Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Werewolf Therapeutics, Inc. - Common Stock
(NQ:
HOWL
)
0.5746
-0.0289 (-4.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Werewolf Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Werewolf Therapeutics Announces Pipeline and Business Updates
December 18, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
November 07, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
October 08, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 03, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
July 09, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the BIO International Convention
June 12, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
May 29, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
May 20, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
May 13, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 08, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
May 05, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
May 05, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
April 17, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 11, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
March 04, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
February 24, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
January 13, 2025
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
November 20, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
November 07, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
October 31, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
June 25, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
June 01, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
